Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence and Consequences of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer: a Prospective Population Based Multicenter Study. The PALN Study

NCT06065891 is registered in ClinicalTrials.gov with Jon Unosson as lead sponsor.

NCT NCT06065891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06065891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence and Consequences of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer: a Prospective Population Based Multicenter Study. The PALN Study
Lead sponsor
Jon Unosson
Phase
Not applicable
Overall status
Recruiting
Start date
September 5, 2023
Completion date
September 5, 2028
Enrollment
300 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lymph node metastasis, pancreas adenocarcinoma, pancreas cancer